Cullinan Therapeutics, Inc. (CGEM)
NASDAQ · Healthcare
Cullinan Therapeutics, Inc. EBITDA 2020–2022
Cullinan Therapeutics, Inc. annual/quarterly ebitda history and growth rate from 2020 to 2022. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Cullinan Therapeutics, Inc. ebitda for the quarter ending March 31, 2022 was -32.6 M, a 2453.57% decrease year-over-year.
- Cullinan Therapeutics, Inc. annual ebitda for 2022 was 144.7 M, a 313.16% decrease from 2021.
- Cullinan Therapeutics, Inc. annual ebitda for 2021 was -67.9 M, a 12.66% increase from 2020.
- Cullinan Therapeutics, Inc. annual ebitda for 2020 was -60.3 M.
EBITDA
QUARTERLY · $B
Cullinan Therapeutics, Inc. EBITDA — FAQ
Cullinan Therapeutics, Inc. (CGEM) ebitda over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CGEM's ebitda history?
The chart and table above show Cullinan Therapeutics, Inc.'s ebitda by year and by quarter, including the growth rate.